Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02534038 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition
A Phase 2 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02534038 is a Phase 2 study that was terminated before completion, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 1 participants.
The verdict
NCT02534038, a Phase 2 study, was terminated before completion, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
Treatment of disinhibition syndrome in participants with Neurodegenerative Disorder.
Interventions
- DRUG Placebo
- DRUG AVP-786
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-12-01 |
| Est. Completion | 2017-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02534038
The ClinicalTrials.gov registry entry for NCT02534038 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02534038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02534038 about?
NCT02534038 is a clinical study titled "Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition". Treatment of disinhibition syndrome in participants with Neurodegenerative Disorder.
What is the current status of trial NCT02534038?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2015-12-01. Estimated completion is 2017-10-03.
What interventions are being tested in trial NCT02534038?
The interventions under investigation include: Placebo (DRUG), AVP-786 (DRUG).
Who is sponsoring clinical trial NCT02534038?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.